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Highlights: 
 
• Polypharmacy (> 5 medications) was present in 39% of patients at the time of 
dementia diagnosis 
• Exposure groups (0-4; 5-9; >10 medications) did not differ in mean MMSE score at 
diagnosis 
• All groups showed a slight increase in MMSE score in the 6 months after dementia 
diagnosis 
• No significant differences were detected between the exposure groups in short- and 
long-term cognitive decline 
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in People with Dementia: a large representative cohort study 
 
 
Abstract 
 
Polypharmacy, defined through the number of medications prescribed, has been linked to a 
range of adverse health outcomes in people with dementia. It is however unclear whether a 
numerical threshold of concurrently prescribed drugs is a suitable predictor for cognitive 
decline. We aimed to test associations between polypharmacy and both short-term (six 
months) and long-term (three years) cognitive trajectories in patients with incident dementia. 
Data from a large mental health and dementia care database in South London a cohort of 
12,148 patients (mean age =80.7 years, 61.1% female, mean MMSE =18.6) clinically 
diagnosed with dementia was identified. We determined the number of medications prescribed 
at dementia diagnosis and defined two exposure groups: polypharmacy (5-9 medication) and 
excessive polypharmacy (> 10 medications), with 0-4 medications as reference group. All Mini 
Mental State Examination (MMSE) scores between one year before and three years after 
dementia diagnosis were ascertained. Effects of polypharmacy on cognitive decline were 
studied using Generalized Additive Models for Location, Scale and Shape and Linear Mixed 
Estimation Models. At the time of dementia diagnosis polypharmacy was present in 3,503 
(28.8%) patients and excessive polypharmacy in 1,235 (10.2%) patients. In all three groups 
MMSE scores initially improved after dementia diagnosis and further decline was detected in 
the time interval from six months to three years after dementia diagnosis. No significant 
differences to the control group were found in relation to polypharmacy or excessive 
polypharmacy, neither in the initial cognitive improvement nor long-term decline. In conclusion, 
polypharmacy defined by the number of drugs does not appear to predict cognitive decline in 
a naturalistic cohort of patients with dementia. More sophisticated tools, considering 
appropriateness of prescribing and the clinical picture, might be better placed to evaluate 
cognitive outcomes in dementia and to make practice and research recommendations. 
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1. Introduction 
 
Polypharmacy, defined as the concurrent use of five or more medications, and multimorbidity 
are more common in people with dementia than in those without the condition (Clague and 
others 2016). More than half of patients with dementia are subject to such a high level of 
prescribing, whereby one or two agents are applied to directly address symptoms of dementia, 
including cognitive decline (Clague and others 2016; Lau and others 2010). Polypharmacy 
has been linked to increased hazards of emergency department attendance, hospitalisation, 
and mortality in this patient group (Mueller and others 2018). While research in general older 
populations has shown that polypharmacy is related to both deficits in cognitive functioning 
and a higher likelihood of developing dementia (Park and others 2017; Rawle and others 
2018), studies on the effects of polypharmacy in patients with an established diagnosis of 
dementia are sparse. In this group, multimorbidity has been linked to worse cognition in cross-
sectional (Doraiswamy and others 2002) but not longitudinal study designs (Melis and others 
2013). Longitudinal research restricted to nursing home residents, about half suffering from 
dementia, suggested a decline in cognitive functioning associated with polypharmacy over 
one year (Vetrano and others 2018), but no studies are available assessing the cognitive 
effects of polypharmacy in incident dementia. Since polypharmacy is associated with worse 
cognition in the general older adults population (Maher and others 2014) and that high 
proportions of people with dementia are subject to polypharmacy (Clague and others 2016), 
there is an urgent need to understand if polypharmacy may be a risk factor for cognitive decline 
in this population.   
 
Given these gaps in the literature, we aimed to evaluate the relationship between 
polypharmacy and both six-months and three-year cognitive decline in a large cohort of 
patients with a first diagnosis of dementia in South East London.  
 
 
2. Methods 
 
2.1 Study population: 
Data for this study were obtained from the South London and Maudsley NHS Foundation Trust 
(SLaM) Clinical Record Interactive Search (CRIS) application. CRIS provides research access 
to more than 300,000 de-identified health records from SLaM, one of Europe’s largest 
healthcare providers for dementia and other mental disorders, serving a population of over 1.3 
million residents (Perera and others 2016; Stewart and others 2009). CRIS has received 
ethical approval as an anonymized data resource (Oxford Research Ethics Committee C, 
reference 08/H0606/71+5) and was used to extract records of patients who received a first 
dementia diagnosis according to ICD-10 criteria (World Health Organisation 2010) from SLaM 
services within the period between 1st Jan 2007 and 30th July 2016. Dementia diagnosis date 
and other data of interest were extracted either from structured fields in the source record or 
from clinical documents through natural language processing algorithms using the General 
Architecture for Text Engineering (GATE) software (Cunningham 2002; Perera and others 
2016).  
 
2.2 Polypharmacy 
The GATE-supported natural language processing algorithm was used to ascertain the 
number of medications recorded in text fields (case notes, clinical correspondence) in a 6-
month window around the dementia diagnosis (Mueller and others 2018; Perera and others 
2016). This serves as a measure for prevalent polypharmacy as patients’ medication might 
not be recorded in electronic health records at the same time as the diagnosis, and has been 
shown to be predictive of hospitalisation and mortality in a cohort from the same source 
population (Mueller and others 2018). In line with the current literature we defined 
polypharmacy as concurrent use of 5-9 medications and excessive polypharmacy as 
prescription of 10 or more medications (Vetrano and others 2013; Vetrano and others 2018), 
whereby prescription of 0-4 medications served as reference condition.  
 
2.3 Covariates 
A range of potential confounders were ascertained at the time of dementia diagnosis, including  
socio-demographic variables (age, gender, marital status, ethnicity (dichotomized to White 
and Non-White), and a neighbourhood-level index of multiple deprivation (Noble and others 
2007)). From structured fields and free-text documents we ascertained the dementia subtype 
diagnosis (Alzheimer’s disease (including mixed-type), vascular dementia, Lewy body 
dementias, unspecified dementia) according to WHO ICD-10 criteria (World Health 
Organisation 2010).  
To measure general physical health, we applied the ‘Problems related to physical illness or 
disability’ subscale of the Health of the Nation Outcome Scales (HoNOS65+) instrument and 
ascertained whether the patient had been hospitalised in the year prior to dementia diagnosis 
using an established linkage to national hospitalisation data (Hospital Episode Statistics, 
available until 31st March 2016 (NHS Digital)). Previous hospitalisation has been linked to 
earlier mortality in this patient group (Mueller and others 2017) and serves as a proxy measure 
for patients at risk of accelerated physical decline. The HoNOS65+ is a standard measure of 
patient welfare used by UK mental health and dementia services (Burns and others 1999) and 
subscales are each rated 0 (no problem) to 4 (severe or very severe problem). Besides 
physical illness, we included subscales measuring mental health symptom severity and 
functional status closest to dementia diagnosis.  To ease interpretation, we dichotomised 
subscales to ‘minor or no problem’ (scores of 0 and 1) and ‘mild to severe problems’ (scores 
2 to 4) (Mueller and others 2017). Lastly, we determined whether patients were prescribed 
acetylcholinesterase inhibitors within the first 6 months after dementia diagnosis, as these 
medications have a direct influence on cognitive trajectories (Perera and others 2014). 
 
2.4 Cognitive decline and statistical methods 
Level of cognitive impairment as measured by Mini-Mental State Examination (MMSE) 
(Folstein and others 1975) was ascertained between one year before and within three years 
after first dementia diagnosis date, and the analysed sample was restricted to patients with at 
least two MMSE score points in the time period between January 2006 and December 2016. 
 
To determine rate of cognitive decline, we initially used Generalized Additive Models for 
Location, Scale and Shape (GAMLSS) (Rigby RA 2005) to visualise the shape of MMSE score 
trajectories for the three cohorts (0-4 medications; 5-9 medications; > 10 medications). 
GAMLSS is not restricted to the linearity assumption and thereby allows the use of non-
parametric smoothing functions in modelling of the parameters of the distribution as functions 
of explanatory variables. Although GAMLSS output provides a helpful way of visualising the 
pattern of cognitive decline within the observation window, it does not permit analyses of 
predictive covariates, confounding and effect modification. Building on previous experience 
using these models (Fazal and others 2017; Perera and others 2014) and by inspecting the 
curves derived from GAMLSS, we concluded that it would be appropriate to use parametric 
methodology in the form of a three-piecewise linear mixed model to estimate cognitive change 
and its predictors. As in previous analysis of these outcomes in this data source (Perera and 
others 2014) we examined the three time components: 12 months prior to the dementia 
diagnosis (segment 1); from dementia diagnosis to 6 months post diagnosis (segment 2; short-
term follow-up); 6 to 36 months post diagnosis (segment 3; long-term follow-up). Slopes and 
slope differences were obtained using Linear Mixed Estimation (LME) methodology. Three-
piece wise model estimates were adjusted for the following covariates: age, gender, ethnicity, 
marital status, deprivation score, dementia subtype, HoNOS65+ symptoms scores (agitation, 
hallucinations and/or delusions, self-injury, substance use, depressed mood, physical illness), 
HoNOS65+ functional problem scores (activities of daily living, living conditions, 
occupational/recreational activities, social relationships), hospitalisation prior to dementia 
diagnosis, and AChEI prescription. We further used the STATA 13 software (Stata Corp LP, 
College Station, TX, USA) to examine baseline differences in the study population across the 
three levels of prescribing (0–4, 5–9, >10 medications) through linear and logistic regression 
models. 
   
 
 
3. Results 
 
We identified 15,441 patients diagnosed with dementia in South London and Maudsley NHS 
Foundation Trust services within the observation period. We excluded 3,293 (21.3%) case 
records due to insufficient MMSE scores within the time window from one year before to three 
years after dementia diagnosis and the final sample consisted of 12,148 people with incident 
dementia.   
 
Mean age (SD) of this cohort was 80.7 (±8.7) years, mean MMSE (SD) at diagnosis 18.6 
(±6.4) and 61.1% of the sample were female. In terms of subtype diagnoses, 7,640 (62.9%) 
were diagnosed with Alzheimer’s disease, 2,214 (18.2%) with vascular dementia, 494 (4.1%) 
with a Lewy body dementia and 1,800 (14.8%) with unspecified or other forms of dementia. 
According to the MMSE scores, most patients were diagnosed in the mild (43.0%) to moderate 
(47.8%) stage of dementia, with only a minority (9.2%) in the severe stage.  
 
The majority of patients (n=7,410; 61.0%) were on 0-4 medications, while polypharmacy (5-9 
medications) was detected in 3,503 (28.8%) and excessive polypharmacy in 1,235 (10.2%) 
patients.  
 
Patient characteristics according to polypharmacy status are presented in Table 1. Compared 
to those taking 0-4 medications, those subject to polypharmacy (5-9 medications) and 
excessive polypharmacy (> 10 medications) were more likely to be male, from a Non-White 
ethnicity background, live in a more deprived areas, less likely to suffer from Alzheimer’s 
disease, but more likely to be diagnosed from with vascular or a Lewy body dementia.  In 
addition, the group were more likely to suffer from neuropsychiatric symptoms as agitation, 
psychosis or depression, and further had higher occurrence of physical health problems and 
previous hospitalisation, as well as more functional difficulties. Only those with excessive 
polypharmacy were significantly younger, less likely to be married or cohabiting, and more 
likely to present with substance use or self-injury when compared to the control population. Of 
note, no differences across groups were detected in MMSE scores at dementia diagnosis and 
proportions of those diagnosed in the severe stage of dementia (MMSE < 9). Patients 
prescribed > 10 medications were least likely to be started on an acetylcholinesterase inhibitor.   
 
For patients taking 0-4 medications 21,760 individual MMSE scores (mean 2.9 per person) 
were available for analysis, for those subject to polypharmacy 11,137 individual MMSE scores 
(mean 3.2 per person), and for patients with excessive polypharmacy 4,671 individual MMSE 
scores (3.8 per person). An initial visual inspection of the non-parametric GAMLSS curves for 
MMSE scores in the three groups (Figure 1) showed a decline in cognitive function during the 
one year prior to the dementia diagnosis, followed by an increase in cognitive function for 
around 6 months after the dementia diagnosis, which was then followed by a steady 
subsequent decline. In this unadjusted model, no clear differences were noted between the 
three groups.  
This result was confirmed through the application of a parametric Linear Estimation Model 
(see Figure 2 and Table 2 for slope coefficients and interaction terms), which adjusted for 
eighteen potential confounders (described in Table 1).  All three groups improved MMSE 
scores improved after a diagnosis of dementia was established (0.59 points per year in 0-4 
medications; 0.17 points per year in 5-9 medications; 0.91 points per year in >10 medication). 
Although the group subject to excessive polypharmacy had the steepest slope coefficient 
when comparing 12 months prior to the 6 months post dementia diagnosis (slope difference 
4.36), the interaction (-1.22; 95% CI -2.83 to 0.38; p<0.05) term was not significant compared 
to the control group. In the same time period, patients taking 5-9 medications had a lower 
slope coefficient (2.53) than those taking 0-4 (3.14), but again the interaction term (0.61; 95% 
CI -0.23 to 1.45; p>0.05) was not significant. All three groups showed a slower decline in the 
time period 6 – 36 months (-2.02 points per year in 0-4 medications; -1.76 points per year in 
5-9 medication; -1.69 points per year in >10 medications) than in the 12 months leading to 
dementia diagnosis, but no significant differences in slopes and interaction terms between the 
control and the polypharmacy groups were detected.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. Discussion 
 
In this study of more than 12,000 patients diagnosed with dementia, including close to 40.000 
individual MMSE score points, the prevalence of polypharmacy and excessive polypharmacy 
at first dementia diagnosis was 29% and 10% respectively. Patients with polypharmacy and 
excessive polypharmacy were more likely to be diagnosed with vascular or Lewy body 
dementia, more liable to suffer from neuropsychiatric symptoms, physical ill health and 
functional problems. Over the short (6 months) and long term (3 years) follow-up we noted no 
significant differences in cognitive status according to baseline polypharmacy levels.   
 
The effect of polypharmacy on cognition has to the best of our knowledge not been studied in 
community samples of people with clinically diagnosed dementia. Data from a multicenter 
cohort (SHELTER) study suggested that both polypharmacy and excessive polypharmacy 
were associated with a worsening of cognitive function over one year in more than 3,000 
nursing home residents as measured by the cognitive performance scale. Half of the 
participants in this study had a diagnosis of dementia and, although this is likely to be an 
underestimation of dementia prevalence in the population (Cherubini and others 2012), 
residents without neurodegenerative disorder were included.  Clearly this nursing home 
resident population is not only substantially smaller than ours, but the inclusion of people 
without dementia and different setting makes comparing the results difficult.  In the SHELTER 
nursing home cohort, patients with lower levels of prescribing had worse cognition and 
functioning, contrary to our population in which higher levels of prescribing were related to 
more frequent functional impairment and no differences were detected in baseline cognitive 
performance. In contrast to community-dwelling older adults, nursing home residents are 
usually ‘frail’ and more commonly present with geriatric syndromes, multiple comorbidities, a 
high rate of functional and cognitive impairment, and polypharmacy (Onder and others 2012). 
Hence, they are more likely than community-dwelling populations to be prescribed 
anticholinergic and potentially inappropriate medications such as proton pump inhibitors, 
bladder antispasmodics and psychotropic drugs, which may cause cognitive impairment or 
worsen existing dementia (Bishara and others 2017; Fox and others 2014; Onder and others 
2012). The higher proportion of these drugs contribution to polypharmacy might explain its 
harmful effect on cognition in this population.  
 
Our study is unique as it uses a broad patient sample with an incident diagnosis of dementia. 
This might have led to the proportion of patients subject to polypharmacy being slightly lower 
than reported in primary care (Clague and others 2016) or nursing home (Vetrano and others 
2018) prevalence data. An interesting finding from our study is that patients with highest 
category polypharmacy were less likely to be prescribed acetylcholinesterase inhibitors, 
AChEIs compared to categories 0-4 and 5-9 medications, but not subject to a faster cognitive 
decline. The lower proportion of patients on acetylcholinesterase inhibitors could be partly 
explained by clinicians’ reluctance to prescribe acetylcholinesterase inhibitors in the context 
of multimorbidity and pre-existing polypharmacy (Bohlken and others 2018). Further, a recent 
meta-analysis of trial data has shown that patients on these medications have a greater annual 
cognitive decline than those not taking them (Kennedy and others 2018), which was not 
necessarily attributed to inefficacy, but rather confounding by indication, which leads to 
prescribing in patients perceived as doing worse.   
  
Although we cannot directly infer this from our data, there are a number of potential 
mechanisms which may explain the absence of an association between polypharmacy and 
cognitive decline.  Polypharmacy may be appropriate to treat a patient with multiple comorbid 
conditions, in particular cardiovascular disease, which has been shown to prevalent in all 
forms of dementia (Clague and others 2016). Although evidence from larger scale randomized 
controlled trials is lacking (Valenti and others 2014), observational research has suggested 
that treatment of vascular risk factors is related to a slower cognitive decline in Alzheimer’s 
disease (Deschaintre and others 2009). Another factor leading to polypharmacy could be drug 
treatment of neuropsychiatric symptoms such as depression, agitation, hallucinations, 
aberrant motor activity, delusions in patients with dementia (Isik and others 2018).  The 
evidence on the influence of psychotropic prescribing on cognitive decline is mixed, with the 
majority suggesting accelerated cognitive decline in relation to antidepressants and 
antipsychotics (Baker and others 2017; Rosenberg and others 2012; Vigen and others 2011), 
while others didn’t identify significant associations (Rocca and others 2007; Tormalehto and 
others 2017). It is thereby possible that successful treatment of neuropsychiatric symptoms 
could lead to better performance on cognitive testing. Lastly, cognitive decline has been 
associated with accelerated physical decline (Fabbri and others 2016), and appropriate 
prescribing to alter the course of multi-morbid long-term conditions might have a positive effect 
on cognition.   
 
Strengths of the current study include a naturalistic sample of the main provider of dementia 
care for the source population, the wide range of potential confounders adjusted for and the 
large numbers of cognitive function recordings obtained, as well as the long follow up for 3 
years after dementia diagnosis, which is a considerably greater period than most previous 
studies. 
The use of routinely collected data also has a number of limitations. First, polypharmacy was 
assessed based on drugs used at the baseline assessment and we did not take into 
consideration changes in drug regimens occurring during the study period. Second, cognitive 
functions were evaluated by only MMSE, which has several limitations, such as ceiling effects 
when used in individuals with high education, probability of false negativity for different 
dementia subtypes, as well as floor effects in those with severe dementia (Monroe and Carter 
2012). However, less than 10% of out sample had an MMSE score of less than ten, and these 
were equally distributed across exposure groups. Third, comorbidity was ascertained through 
hospitalisation prior to dementia diagnosis and the HoNOS65+ physical illness subscale. 
Although the HoNOS65+ physical illness subscale is relatively brief without details on the 
specific long-term conditions defining its score, it has been shown to a have useful predictive 
validity of adverse outcomes in this patient population (Mueller and others 2018; Mueller and 
others 2017). Fourth, guideline from the National Institute for Health and Care Excellence 
states that those with mild-to-moderate dementia should be given the opportunity to take part 
in a structured group cognitive stimulation programme and independence should be promoted 
trough interventions as ADL skill training facilitated by occupational therapists (National 
Institute for Health and Care Excellence (NICE) 2006).  Although patients this sample are 
under the care of a specialist provider of mental health and dementia care, we are unable to 
ascertain which of our patients were offered these interventions and this might have influenced 
our results.  Fifth, other potential risk factors for cognitive decline such as health behaviours 
or level of education are not directly captured and only approximated through an index of 
neighbourhood-level socio-economic deprivation (Noble and others 2007).  Last, the results 
may also be affected by residual confounders which we were unable to adjust for, including 
medication adherence. 
4.1 Conclusions 
Although polypharmacy has been related to concrete adverse outcomes as mortality or 
hospitalisation in people with dementia (Mueller and others 2018), categorical classification of 
polypharmacy does not appear to predict MMSE measured cognitive decline. Optimal drug 
treatment for older people with dementia is complex and may lead to appropriate 
polypharmacy, since comorbid medical conditions such as cardiovascular diseases and 
neuropsychiatric symptoms are common. These comorbidities do not only lead to functional 
decline and difficulties in the management of the dementia leading, but also to prescribing of 
medications bound to worsen cognition. Conversely, potential prescribing omissions might 
also have adverse effects on cognitive performance. Therefore, in order to predict cognitive 
decline, the use of more detailed scales, e.g. scales measuring anticholinergic burden 
(Bishara and others 2016; Landi and others 1999),  might be more helpful than purely numeric 
thresholds.  
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Table 1: Characteristics of patients with dementia classified according to medication usage 
 
Risk factors 0-4 
medications 
(n=7,410) 
5-9 
medications 
(n=3,503) 
≥10 
medications 
(n=1,235) 
P1 (5-9 vs 
0-4) 
P1 (≥10 vs 
0-4) 
Socio-demographic status and cognitive function2    
Mean age at dementia diagnosis (SD) 81.0 (8.5) 81.0 (8.2) 78.0 (10.4) 0.966 <0.001 
Female gender (%) 62.8% 59.7% 54.5% 0.002 <0.001 
Non-White ethnicity (%)  22.8% 27.4% 28.4% <0.001 <0.001 
Married or cohabiting status (%)  34.0% 34.9% 30.1% 0.394 0.008 
Mean index of deprivation (SD) 26.5 (11.3) 28.1 (10.8) 29.6 (10.2) <0.001 <0.001 
Mean MMSE score at diagnosis (SD) 18.6 (6.4) 18.7 (6.3) 18.4 (6.4) 0.570 0.181 
Mild (MMSE > 21) 43.2% 44.0% 39.2% 0.445 0.006 
Moderate (MMSE 10-20) 47.4% 47.4% 51.5% 0.972 0.014 
Severe (MMSE < 9) 9.4% 8.6% 9.3% 0.189 0.904 
Dementia subtype      
Alzheimer’s disease   65.8% 62.1% 47.2% <0.001 <0.001 
Vascular dementia   15.9% 21.1% 24.3% <0.001 <0.001 
Lewy body dementias (Dementia with Lewy bodies 
or Parkinson’s disease dementia) 
2.8% 4.9% 9.1% <0.001 <0.001 
Unspecified or other dementia 15.4% 11.9% 19.4% <0.001 <0.001 
HoNOS65+ symptoms/disorders (%)2 
Agitation 14.7% 19.7% 34.7% <0.001 <0.001 
Hallucinations and/or delusions 10.5% 15.4% 30.7% <0.001 <0.001 
Non-accidental self-injury 1.0% 1.2% 4.6% 0.342 <0.001 
Substance use 3.1% 3.6% 5.7% 0.247 <0.001 
Depressed mood 11.7% 18.0% 27.8% <0.001 <0.001 
Physical illness or disability 47.9% 59.6% 72.1% <0.001 <0.001 
HoNOS65+ functional problems (%)2    
Activities of daily living 55.8% 60.7% 70.5% <0.001 <0.001 
Living conditions 12.1% 12.5% 20.3% 0.517 <0.001 
Occupational / recreational activities 29.0% 33.8% 46.0% <0.001 <0.001 
Social relationships 13.9% 17.7% 31.7% <0.001 <0.001 
AChEI prescription3 25.8% 27.5% 20.5% 0.062 <0.001 
Hospitalization prior to dementia diagnosis4 47.6% 55.1% 72.2% <0.001 <0.001 
 
1 Using linear regression for continuous and logistic regression for ordinal variables 
2 Closest to the time of dementia diagnosis 
3 Whether patient was prescribed an Acetylcholinesteraseinhibitor within 6 months of dementia 
diagnosis 
4  Whether the patient was admitted to an acute hospital in the 1 year prior to dementia diagnosis 
from Hospital Episode Statistics
Table 2: Analysis of MMSE change from one year prior to three years after dementia diagnosis 
 
MMSE slopes  and differences 
0-4 medications 
  
5-9 medications 
  
≥10 medications 
(n=7410) (n=3503) (n=1235) 
MMSE slope 12 - 0 months before dementia 
diagnosis -2.55 
 -2.35  -3.44 
MMSE slope 0 - 6 months after dementia diagnosis 0.59  0.17  0.91 
MMSE slope 6 - 36 months after dementia 
diagnosis -2.02 
 -1.76  -1.69 
MMSE slope difference between 0 - 6 months after 
and 12 - 0 months before dementia diagnosis  3.14 (3.67, 2.62) 
 2.53 (3.32, 1.73)  4.36 (5.71, 3.01) 
Interaction term of slope differences (0-4 vs. 5-9) 
(0-4 vs. ≥10)  
 0.61 (-0.23 to 1.45 )  - 1.22 (-2.83 to 0.38)  
MMSE slope difference between 6 - 36 months 
after and 12 - 0 months before dementia diagnosis 0.53 (0.90, 0.17) 
 0.59 (1.15, 0.03)  1.76 (2.67, 0.84) 
Interaction  term of slope differences (0-4 vs. 5-9) 
(0-4 vs. ≥10)   - 0.06 (-0.65 to 0.54)   - 1.23 (-3.22 to 0.74)   
 
Slope differences and interactions are adjusted for the following co-variates: Age, gender, ethnicity, deprivation score, dementia subtype, 
HoNOS65+ symptom/disorder and functional problem scores, AChEI prescription and previous hospitalisation.  
 
 
Figure 1: Comparison of longitudinal change in MMSE in the samples using non-parametric GAMLSS methodology (not adjusted 
for co-variates) 
 
   
0-4 medications (n=7,410) 5-9 medications (n=3,503) ≥10 medications (n=1,235) 
 
 
Figure 2: Comparison of non-parametric Linear Mixed Models of the rate of cognitive decline allowing adjustment for co-variates 
 
   
0-4 medications (n=7410) 5-9 medications (n=3503) ≥10 medications (n=1235) 
 
Slopes are adjusted for the following co-variates: Age, gender, ethnicity, deprivation score, dementia subtype, HoNOS65+ symptom/disorder 
and functional problem scores, AChEI prescription and previous hospitalisation.  
 
 
 
